This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Magrolimab
- DrugBank Accession Number
- DB16225
- Background
Magrolimab is under investigation in clinical trial NCT02953782 (Trial of Magrolimab (Hu5f9-g4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer).
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- 5F9
- Anti-cd47 monoclonal antibody hu5f9-g4
- Immunoglobulin g4-kappa, anti-(homo sapiens cd47 (integrin associated protein, iap, mer6, oa3)), monoclonal antibodygamma4 heavy chain (1-444) (vh (homo sapiens ighv1-3*01 (87.8%)-(ighd)-ighj4*01 (100%)) (8.8.10) (1-117)-homo sapiens ighg4*01 (ch1 (118-2
- Immunoglobulin g4(225-proline), anti-(human cd47 antigen) (human-mus musculus monoclonal hu5f9-g4 .gamma.4-chain), disulfide with human-mus musculus monoclonal hu5f9-g4 .kappa.-chain, dimer
- Magrolimab
- External IDs
- HU5F9 G4
- Hu5F9-G4
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Magrolimab. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Magrolimab. Aducanumab The risk or severity of adverse effects can be increased when Aducanumab is combined with Magrolimab. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Magrolimab. Alirocumab The risk or severity of adverse effects can be increased when Alirocumab is combined with Magrolimab. Amivantamab The risk or severity of adverse effects can be increased when Magrolimab is combined with Amivantamab. Anifrolumab The risk or severity of adverse effects can be increased when Anifrolumab is combined with Magrolimab. Ansuvimab The risk or severity of adverse effects can be increased when Magrolimab is combined with Ansuvimab. Anthrax immune globulin human The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Magrolimab. Antilymphocyte immunoglobulin (horse) The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Magrolimab. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 90YIEHRFJ9
- CAS number
- 2169232-81-7
References
- General References
- Not Available
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Active Not Recruiting Treatment Myelodysplastic Syndrome 1 3 Recruiting Treatment Acute Myeloid Leukemia 2 2 Active Not Recruiting Treatment Myeloid Malignancies 1 2 Recruiting Treatment Classical Hodgkin's Lymphoma / Hodgkin's Lymphoma / Refractory Classical Hodgkin's Lymphoma / Relapsed Classical Hodgkin's Lymphoma 1 2 Recruiting Treatment Metastatic Colorectal Cancer (CRC) 1 2 Recruiting Treatment Multiple Myeloma (MM) 1 2 Recruiting Treatment Solid Tumors 1 2 Recruiting Treatment Squamous Cell Carcinoma of the Head and Neck (SCCHN) 1 2 Recruiting Treatment Triple-Negative Breast Cancer 1 1 Active Not Recruiting Treatment Hematological Malignancy 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at December 15, 2020 18:16 / Updated at December 08, 2022 21:18